Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuract
- Development stage
- Phase 2
- Lead developer
- Origin BioMed
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
**Neuract** is an investigational topical cream developed by Origin BioMed for short-term relief of neuropathic lower back pain. It was evaluated against placebo in a randomized, double-blind clinical study involving a single approximately 1 mL topical application, with pain effects monitored for up to 8 hours. Publicly available trial information identifies the product and its clinical use, but does not disclose a definitive active-ingredient composition, molecular target, or mechanism of action; therefore, Neuract should not be conflated with the unrelated Colombian Neuract rivastigmine transdermal patch product.
- Brand names
- Neuract
- Other names
- Neuract cream
Beyond the preview
Go deeper on Neuract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuract.